OSCR

Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects.

Overview

Authors: Youfang Cao1, Brian A. Willis1, Kanta Horie1,2,3, Kristin R. Wildsmith1, Akihiko Koyama1, Pallavi Sachdev1, Natasha Penner1, Arnaud Charil1, Michael Irizarry1, Larisa Reyderman1
  1. Translational Sciences, Eisai Inc.,Nutley, NJ USA
  2. Department of Neurology, Washington University School of Medicine,St Louis, USA
  3. The Tracy Family Stable Isotope Labeling Quantitation (SILQ) Center, Washington University School of Medicine,St Louis, USA
Institutions: Translational Sciences, Eisai Inc.,Nutley, NJ USA; Washington University in St. Louis (United States)
Journal: NPJ systems biology and applications, volume 12, issue 1, article 55
Dates: received 28 June 2025; accepted 13 February 2026; published online 6 March 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1038/s41540-026-00677-4 · PMID 41792131 · PMCID PMC13096144 · OpenAlex W7134062818
Open access: gold, a free copy (OpenAlex)
Status: code on request
Categories: computational modeling (no new data) (modality), human (organism), Alzheimer's / dementia (population)
Methods: Statistics, Connectivity
Keywords: Computational biology and bioinformatics, Diseases, Neurology, Neuroscience
MeSH: Alzheimer Disease*, Aged, Amyloid beta-Peptides, Cognitive Dysfunction, Computer Simulation, Disease Progression, Female, Humans, Male, tau Proteins (* major topic)
Topic: Dementia and Cognitive Impairment Research (Psychiatry and Mental health, Medicine), according to OpenAlex
Funding: U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2, W81XWH-12, W81XWH1220012, AG024904); Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012); Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012); Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012); Pfizer (AG024904, W81XWH-12-2-0012, U01 AG024904); Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904); University of Southern California (W81XWH-12-2-0012, U01 AG024904); F. Hoffmann-La Roche (W81XWH-12-2-0012, AG024904, U01 AG024904); Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012); Alzheimer's Disease Neuroimaging Initiative (W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2); BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904); Novartis Pharmaceuticals Corporation (W81XWH-12-2-0012, U01 AG024904, AG024904); Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012); Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904); Servier (AG024904, W81XWH-12-2-0012, U01 AG024904); H. Lundbeck A/S (U01 AG024904, AG024904, W81XWH-12-2-0012); IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904); National Institutes of Health (3u01ag024904-10s2, W81XWH, W81XWH-12-2-0012, U01-AG024904, AG024904); Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904); Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
Citations: not cited yet (Europe PMC); 40 references in the paper

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

Code availability statement

The paper has a code availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it says that the code is available on request

Read it in the paper: doi.org/10.1038/s41540-026-00677-4.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Data availability statement

The paper has a data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it says that the data are available on request

Read it in the paper: doi.org/10.1038/s41540-026-00677-4.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 30 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 4 keywords, 10 MeSH terms, 20 funders, 40 references.

Cite

This paper

Cao, Y., Willis, B. A., Horie, K., Wildsmith, K. R., Koyama, A., Sachdev, P., Penner, N., Charil, A., Irizarry, M., & Reyderman, L. (2026). Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects. NPJ systems biology and applications, 12(1), 55. https://doi.org/10.1038/s41540-026-00677-4

BibTeX

@article{cao2026neuro,
author = {Cao, Youfang and Willis, Brian A. and Horie, Kanta and Wildsmith, Kristin R. and Koyama, Akihiko and Sachdev, Pallavi and Penner, Natasha and Charil, Arnaud and Irizarry, Michael and Reyderman, Larisa},
title = {{Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects}},
journal = {NPJ systems biology and applications},
year = {2026},
month = mar,
volume = {12},
number = {1},
pages = {55},
publisher = {Nature Publishing Group},
issn = {2056-7189},
doi = {10.1038/s41540-026-00677-4},
url = {https://doi.org/10.1038/s41540-026-00677-4},
pmid = {41792131},
pmcid = {PMC13096144}
}

RIS

TY - JOUR
AU - Cao, Youfang
AU - Willis, Brian A.
AU - Horie, Kanta
AU - Wildsmith, Kristin R.
AU - Koyama, Akihiko
AU - Sachdev, Pallavi
AU - Penner, Natasha
AU - Charil, Arnaud
AU - Irizarry, Michael
AU - Reyderman, Larisa
TI - Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects
T2 - NPJ systems biology and applications
J2 - NPJ Syst Biol Appl
PY - 2026
DA - 2026/03/06
VL - 12
IS - 1
SP - 55
SN - 2056-7189
PB - Nature Publishing Group
DO - 10.1038/s41540-026-00677-4
UR - https://doi.org/10.1038/s41540-026-00677-4
LA - en
ER -

CSL-JSON

{
"id": "10.1038/s41540-026-00677-4",
"type": "article-journal",
"title": "Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects",
"container-title": "NPJ systems biology and applications",
"author": [
{
"family": "Cao",
"given": "Youfang"
},
{
"family": "Willis",
"given": "Brian A."
},
{
"family": "Horie",
"given": "Kanta"
},
{
"family": "Wildsmith",
"given": "Kristin R."
},
{
"family": "Koyama",
"given": "Akihiko"
},
{
"family": "Sachdev",
"given": "Pallavi"
},
{
"family": "Penner",
"given": "Natasha"
},
{
"family": "Charil",
"given": "Arnaud"
},
{
"family": "Irizarry",
"given": "Michael"
},
{
"family": "Reyderman",
"given": "Larisa"
}
],
"container-title-short": "NPJ Syst Biol Appl",
"volume": "12",
"issue": "1",
"page": "55",
"DOI": "10.1038/s41540-026-00677-4",
"PMID": "41792131",
"PMCID": "PMC13096144",
"ISSN": "2056-7189",
"publisher": "Nature Publishing Group",
"URL": "https://doi.org/10.1038/s41540-026-00677-4",
"language": "en",
"issued": {
"date-parts": [
[
2026,
3,
6
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1002/14651858.cd016297
Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Journal: The Cochrane database of systematic reviews
In common: Alzheimer's / dementia, 4 references
[2] doi:10.1002/dad2.70484
AST/ALT, <i>APOE</i> ε4, and Alzheimer's disease progression: A longitudinal cohort study.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
In common: Alzheimer's / dementia, 3 references
[3] doi:10.1186/s13024-026-00965-x
Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.
Journal: Molecular neurodegeneration
In common: Alzheimer's / dementia, 3 references
[4] doi:10.1002/dad2.70475
Plasma GFAP and language-network tau mediate the effect of amyloid burden on semantic fluency: A mediation analysis.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
In common: Alzheimer's / dementia, 3 references
[5] doi:10.1093/brain/awaf413 [code]
Estimating the time course of biomarker changes in Alzheimer's disease.
Journal: Brain : a journal of neurology
In common: Alzheimer's / dementia, 3 references
[6] doi:10.1038/s41467-026-75895-9
Distinct Filament Conformation for Receptor-Bound Amyloid-β from Alzheimer's Disease Brain.
Journal: Nature communications
In common: Alzheimer's / dementia, 3 references
[7] doi:10.1080/19490976.2026.2676162 [code]
Microbiome functional gene pathways are indicative of cognitive performance in older adults at risk for Alzheimer's disease.
Journal: Gut microbes
In common: Alzheimer's / dementia, 3 references
[8] doi:10.1002/hbm.70508 [code]
Cyclic 2.5D Perceptual Loss for Cross-Modal 3D Medical Image Synthesis: T1w MRI to Tau PET.
Journal: Human brain mapping
In common: Alzheimer's / dementia, 3 references
[9] doi:10.1186/s13195-026-02036-1 [code]
Genetic drivers of progression in Alzheimer's disease are distinct from disease risk.
Journal: Alzheimer's research & therapy
In common: Alzheimer's / dementia, 3 references
[10] doi:10.1038/s41467-026-71831-z [code]
Dysfunction of the episodic memory network in the Alzheimer's disease cascade.
Journal: Nature communications
In common: Alzheimer's / dementia, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.